MicroRNA-448 targets SATB1 to reverse the cisplatin resistance in lung cancer via mediating Wnt/β-catenin signalling pathway.

Journal of Biochemistry
Mei-Ying NingJing Zhao

Abstract

This study aims to examine whether miR-448 reverses the cisplatin (DDP) resistance in lung cancer by modulating SATB1. QRT-PCR and immunohistochemistry were used to examine the miR-448 and SATB1 expressions in DDP-sensitive and -resistant lung cancer patients. A microarray was used to investigate the cytoplasmic/nucleic ratio (C/N ratios) of genes in A549 cells targeted by miR-448, followed by Dual-luciferase reporter gene assay. A549/DDP cells were transfected with miR-448 mimics/inhibitors with or without SATB1 siRNA followed by MTT assay, Edu staining, flow cytometry, qRT-PCR and western blotting. MiR-448 was lower but SATB1 was increased in DDP-resistant patients and A549/DDP cells. And the patients showed low miR-448 expression or SATB1 positive expression had poor prognosis. SATB1, as a target gene with higher C/N ratios (>1), was found negatively regulated by miR-448. Besides, miR-448 inhibitors increased resistance index of A549/DDP cells, promoted cell proliferation, increased cell distribution in S phrase, declined cell apoptosis and activated Wnt/β-catenin pathway. However, SATB1 siRNA could reverse the above effect caused by miR-448 inhibitors. MiR-448 targeting SATB1 to counteract the DDP resistance of lung cancer ...Continue Reading

References

Mar 20, 2010·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Fazlul H SarkarShadan Ali
Mar 1, 2012·Current Pharmaceutical Design·Jiujie CuiKeping Xie
Nov 28, 2012·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Yu WangWen-chao Liu
Mar 1, 2013·Nature·Sebastian MemczakNikolaus Rajewsky
Jun 25, 2015·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Y LvC Fang
Jun 26, 2015·Digestive Diseases and Sciences·Zheng ChenZekuan Xu
Sep 16, 2016·Anticancer Research·Alina Jankowska-KonsurPiotr Dziegiel
Dec 17, 2017·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Jun DengSongping Wang
Jan 31, 2018·Cancer Investigation·Meng DingLijun Mao
May 17, 2018·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·Qilai ChengLonghuo Wu
May 18, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Krishna P SunkaraMary Bebawy
Nov 10, 2018·Evidence-based Complementary and Alternative Medicine : ECAM·Ying XiongChun Wang
Nov 11, 2018·Oncogene·Rutika Naik, Sanjeev Galande
Mar 9, 2019·Molecular and Clinical Oncology·Laura GiuntiIacopo Sardi
Mar 27, 2019·Journal of Cellular Biochemistry·Jie GaoZhiming Shi
Jun 19, 2019·Bioengineered·Bing Liu, Xuerong Sun

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.